(Q34198775)

31 July 2017

Cilengitide in patients with recurrent glioblastoma: the results of NABTC 03-02, a phase II trial with measures of treatment delivery (English)

1 reference

31 July 2017

phase II clinical trial

0 references

0 references

1 reference

5

Patrick Y Wen

1 reference

31 July 2017

7

Timothy Cloughesy

1 reference

31 July 2017

Mark R Gilbert

1

1 reference

31 July 2017

John Kuhn

2

1 reference

31 July 2017

Kathleen R Lamborn

3

1 reference

31 July 2017

Frank Lieberman

4

1 reference

31 July 2017

Minesh Mehta

6

1 reference

31 July 2017

Andrew B Lassman

8

1 reference

31 July 2017

Lisa M Deangelis

9

1 reference

31 July 2017

Susan Chang

10

1 reference

31 July 2017

Michael Prados

11

1 reference

31 July 2017

8 July 2011

1 reference

Journal of Neuro-Oncology

31 July 2017

1 reference

31 July 2017

106

1 reference

31 July 2017

1

1 reference

31 July 2017

147-153

1 reference

https://scigraph.springernature.com/pub.10.1007/s11060-011-0650-1

31 July 2017

0 references

cites work

Phase I/IIa study of cilengitide and temozolomide with concomitant radiotherapy followed by cilengitide and temozolomide maintenance therapy in patients with newly diagnosed glioblastoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4351869

Patterns of relapse and prognosis after bevacizumab failure in recurrent glioblastoma

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4351869

Cilengitide modulates attachment and viability of human glioma cells, but not sensitivity to irradiation or temozolomide in vitro

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4351869

Randomized phase II study of cilengitide, an integrin-targeting arginine-glycine-aspartic acid peptide, in recurrent glioblastoma multiforme

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4351869

Progression-free survival: an important end point in evaluating therapy for recurrent high-grade gliomas

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4351869

New molecular targets in malignant gliomas

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4351869

Phase I and correlative biology study of cilengitide in patients with recurrent malignant glioma.

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4351869

Phase I and pharmacokinetic study of continuous twice weekly intravenous administration of Cilengitide (EMD 121974), a novel inhibitor of the integrins αvβ3 and αvβ5 in patients with advanced solid tumours

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4351869

Outcomes and prognostic factors in recurrent glioma patients enrolled onto phase II clinical trials

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4351869

The role of alphav integrins during angiogenesis: insights into potential mechanisms of action and clinical development.

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4351869

Invasive behaviour of human gliomas is mediated by interindividually different integrin patterns.

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4351869

Expression of integrin alpha v beta 3 in small blood vessels of glioblastoma tumors.

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4351869

Stimulation of endothelial cell migration by vascular permeability factor/vascular endothelial growth factor through cooperative mechanisms involving the alphavbeta3 integrin, osteopontin, and thrombin.

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4351869

5 July 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-011-0650-1

Human malignant glioma therapy using anti-alpha(v)beta3 integrin agents.

21 January 2018

1 reference

Crossref

https://api.crossref.org/works/10.1007%2FS11060-011-0650-1

Phase I clinical trial of cilengitide in children with refractory brain tumors: Pediatric Brain Tumor Consortium Study PBTC-012.

21 January 2018

1 reference

Crossref

https://api.crossref.org/works/10.1007%2FS11060-011-0650-1

Alpha(v)beta3 and alpha(v)beta5 integrin expression in glioma periphery.

21 January 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4351869

Preferential susceptibility of brain tumors to the antiangiogenic effects of an alpha(v) integrin antagonist

28 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4351869

Role of integrin alpha(v)beta3 in vascular biology

28 October 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/21739168

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Definition of Two Angiogenic Pathways by Distinct alpha(v) Integrins

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/21739168

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1007/S11060-011-0650-1

1 reference

Dimensions Publication ID

31 July 2017

0 references

1 reference

31 July 2017

1 reference